Koullias G J, Kouraklis G P, Raftopoulos I S, Davaris P S, Papadopoulos S A, Golematis B C
1st Department of Propedeutic Surgery, Athens Medical School, Hippocration General Hospital, Greece.
J Surg Oncol. 1996 Nov;63(3):166-71. doi: 10.1002/(SICI)1096-9098(199611)63:3<166::AID-JSO6>3.0.CO;2-B.
Evidence exists that estrogens influence the action of epidermal growth factor (EGF) and its receptor (EGF-R) at multiple levels. Estrogen and antiestrogen action on gastric and other gastrointestinal malignancies has been evaluated by several groups with conflicting results, and EGF-R has been implicated in the current growth factor-mediated models for gastric cancer progression.
ERs and EGF-Rs were detected immunohistochemically in a total of 53 advanced gastric carcinomas using monoclonal antibodies (mAbs) to human ERs and EGF-Rs.
ERs were expressed in 30 (56%) and EGF-Rs in 20 (38%) of the gastric tumors. ER(+) gastric tumors were closely associated with the intestinal type (P < 0.01), whereas EGF-R(+) tumors were significantly correlated with poor differentiation status and ER(+) expression (P < 0.01). Of EGF-R(+) tumors, 85% were also ER(+). EGF-R and ER co-expression was demonstrated in 17 tumors (32% of the group). These cases were significantly corelated with poor differentiation and large tumor size upon resection (P < 0.05).
ER and EGF-R co-expression indicates that a functional interaction between estrogens and EGF may exist in gastric cancer and that when such an interaction becomes operative, it may lead to dedifferentiation and increased tumor growth.
有证据表明雌激素在多个水平上影响表皮生长因子（EGF）及其受体（EGF-R）的作用。几个研究小组对雌激素和抗雌激素对胃癌及其他胃肠道恶性肿瘤的作用进行了评估，结果相互矛盾，并且在目前关于胃癌进展的生长因子介导模型中涉及到了EGF-R。
使用针对人雌激素受体（ERs）和EGF受体（EGF-Rs）的单克隆抗体（mAbs），通过免疫组织化学方法检测了总共53例进展期胃癌中的ERs和EGF-Rs。
在30例（56%）胃肿瘤中检测到ERs表达，在20例（38%）中检测到EGF-Rs表达。ER(+)胃肿瘤与肠型密切相关（P < 0.01），而EGF-R(+)肿瘤与低分化状态和ER(+)表达显著相关（P < 0.01）。在EGF-R(+)肿瘤中，85%也为ER(+)。在17例肿瘤（占该组的32%）中证实了EGF-R和ER的共表达。这些病例与切除时的低分化和肿瘤大尺寸显著相关（P < 0.05）。
ER和EGF-R的共表达表明在胃癌中雌激素和EGF之间可能存在功能相互作用，并且当这种相互作用起作用时，可能导致去分化和肿瘤生长增加。
